相关实验视频
Updated: Jan 17, 2026

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
817
通过粉样蛋白和蛋白PET确定阿尔茨海默病的病期
Derek R Johnson1, Heather J Wiste2, Val Lowe1
1Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Brain : a journal of neurology
|September 20, 2025
概括
这项研究建立了定子发射断层扫描 (PET) 切割点,以定义阿尔茨海默病 (AD) 的四个生物阶段. 这些阶段与认知衰退和疾病进展相关,验证了AD生物标志物研究的新框架.
科学领域:
- 神经成像是一种神经成像.
- 生物标志物 生物标志物
- 神经学 神经学
背景情况:
- 阿尔茨海默病协会提出了一个概念框架,用于阿尔茨海默病 (AD) 生物分期使用粉样蛋白和定子发射断层扫描 (PET) 成像.
- 对于这种分期框架的临床应用,需要特定的tau PET切割点.
研究的目的:
- 通过识别有意义的tau PET切割点,实现和评估AD生物分期.
- 定义四个生物阶段,并描述每个阶段内的参与者特征.
主要方法:
- 分析了来自梅奥诊所队列的896名参与者和来自阿尔茨海默病神经成像计划 (ADNI) 队列的328名参与者.
- 使用高斯混合模型在中间时和时平行区域识别TAU PET切点.
- 生物阶段与临床诊断和认知评估的相关性 (迷你精神状态检查,临床痴呆症评分和框).
主要成果:
- 经验性TAU PET切割点被确定以定义AD的四个不同的生物阶段.
- 增加生物阶段与较高的轻度认知障碍和痴呆症诊断的可能性显著相关.
- 认知表现的恶化与生物阶段的进步相关,在初级和验证队列中一致.
结论:
- 这项研究为阿尔茨海默病的四阶段生物分期系统提供了经验验验证,该系统使用粉样蛋白和蛋白PET.
- 已识别的tau PET切割点使概念框架变得可操作,使得临床应用和对不同AD亚型的进一步研究成为可能.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825

